BG Medicine Story

BG Medicine -- USA Stock  

USD 0.05  0.01  25.00%

Macroaxis does not monitor all media channels or aggregates social signals for BG Medicine. But even though we do not provide professional-grade financial sentiment analysis on BG Medicine, we do publish noise-free headlines that can be used to derive useful patterns or even a trading strategy for BG Medicine. Check also BG Medicine Hype Analysis, BG Medicine Correlation and BG Medicine Performance.
Acquisition by Stelios Papadopoulos of 4205 shares of BG Medicine subject to Rule 16b-3
Filed transaction by Bg Medicine Inc director. Grant, award or other acquisition pursuant to Rule 16b-3

BG Medicine Inc insider trading alert for grant of stock option (right to buy) by Stelios Papadopoulos, the corporate stakeholder, on January 3, 2018. This event was filed by Bg Medicine Inc with SEC on 2013-06-14. Statement of changes in beneficial ownership - SEC Form 4

Cash Floor Correlation

Click cells to compare fundamentals   View All Correlations

Story Momentum

This media report from MacroaxisInsider distributed on January 3, 2018 was a factor to the next trading day price appreciation.The overall trading delta against the next closing price was 25.00% . The overall trading delta when the story was published against the current closing price is 0.00% .

Similar stores for BG Medicine

Bowling Green Daily NewsFull coverage
over a month ago at 
Vanguard Tax-Exempt Bond ETF Stake Boosted by BBT Securities LLC
registrarjournal.comFull coverage
over two months ago at 
Opgen Inc
satPRnews Full coverage
over three months ago at 
BG Medicine and BioTelemetry Financial Analysis
patch News
Dispatch Tribunal - Jan 4, 2018 The product business segment focuses on the development, manufacturing, testing and marketing of medical devices to medical companies, clinics and hospitals. Head-To-Head Comparison BG Medicine and BioTelemetry - Week Herald

Did you try this?

Run CEO Directory Now

CEO Directory

Screen CEOs from public companies around the world
Hide  View All  NextLaunch CEO Directory


EBITDA Comparative Analysis
      BG Medicine Comparables 
BG Medicine is currently under evaluation in ebitda category among related companies. EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.
Check also BG Medicine Hype Analysis, BG Medicine Correlation and BG Medicine Performance. Please also try Premium Stories module to follow macroaxis premium stories from verified contributors across different equity types, categories and coverage scope.